Literature DB >> 22398087

Colorectal cancer screening and surveillance in Crohn's colitis.

Robert J Basseri1, Benjamin Basseri, Maria E Vassilaki, Gil Y Melmed, Andrew Ippoliti, Eric A Vasiliauskas, Philip R Fleshner, Juan Lechago, Bing Hu, Dror Berel, Stephan R Targan, Konstantinos A Papadakis.   

Abstract

AIMS: To assess colonoscopic screening and surveillance for detecting neoplasia in patients with long-standing colonic Crohn's disease (CD). PATIENTS AND METHODS: Colonoscopy and biopsy records from patients with colonic CD were evaluated at the Cedars-Sinai Inflammatory Bowel Disease Center during a 17-year period (1992-2009).
RESULTS: Overall, 904 screening and surveillance examinations were performed on 411 patients with Crohn's colitis (mean 2.2 examinations per patient). The screening and surveillance examinations detected neoplasia in 5.6% of the patient population; 2.7% had low-grade dysplasia (LGD) (n=11), 0.7% had high-grade dysplasia (HGD) (n=3), and 2.2% had carcinoma (anal carcinoma n=3; rectal carcinoma n=6). Mean age of CD diagnosis was 25.6±0.8 years in those with normal examinations, compared to 17.7±2.7 years (p<0.001) in those with HGD, 36.85±1.43 in those with LGD (p=0.021) and 28.32±3.24 years in those with any dysplasia/cancer (p=0.034). Disease duration in patients with normal examinations was 19.1±0.5 years, compared to 36.8±4.4 years (p<0.001) in HGD, 16.88±2.59 in those with LGD (p=0.253) and 30.68±4.03 years in those with any dysplasia/cancer (p=0.152). The mean interval between examinations was higher in HGD (31.5±9.4 months) compared to those with normal colonoscopies (12.92±1.250 months; p=0.002).
CONCLUSIONS: We detected cancer or dysplasia in 5.6% of patients with long-standing Crohn's colitis enrolled in a screening and surveillance program. Younger age at diagnosis of CD, longer disease course, and greater interval between exams were risk factors for the development of dysplasia.
Copyright © 2012 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22398087     DOI: 10.1016/j.crohns.2012.01.005

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  11 in total

1.  Hypermethylation of ITGA4, TFPI2 and VIMENTIN promoters is increased in inflamed colon tissue: putative risk markers for colitis-associated cancer.

Authors:  Christian Gerecke; Bettina Scholtka; Yvonne Löwenstein; Isabel Fait; Uwe Gottschalk; Dorothee Rogoll; Ralph Melcher; Burkhard Kleuser
Journal:  J Cancer Res Clin Oncol       Date:  2015-04-23       Impact factor: 4.553

Review 2.  Strategies for detecting colon cancer in patients with inflammatory bowel disease.

Authors:  William A Bye; Tran M Nguyen; Claire E Parker; Vipul Jairath; James E East
Journal:  Cochrane Database Syst Rev       Date:  2017-09-18

Review 3.  State-of-the-art surgery for Crohn's disease: Part II-colonic Crohn's disease and associated neoplasms.

Authors:  Anne Macleod; Sandra L Kavalukas; Katharina M Scheurlen; Susan Galandiuk
Journal:  Langenbecks Arch Surg       Date:  2022-06-22       Impact factor: 3.445

4.  Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer.

Authors:  Jochen K Lennerz; Kimberley W J van der Sloot; Long Phi Le; Julie M Batten; Jae Young Han; Kenneth C Fan; Corey A Siegel; Amitabh Srivastava; Do Youn Park; Jey-Hsin Chen; Bruce E Sands; Joshua R Korzenik; Robert D Odze; Dora Dias-Santagata; Darrell R Borger; Hamed Khalili; A John Iafrate; Gregory Y Lauwers
Journal:  Int J Colorectal Dis       Date:  2016-03-30       Impact factor: 2.571

5.  Newly Diagnosed Colonic Adenocarcinoma: The Presenting Sign in a Young Woman with Undiagnosed Crohn's Disease in the Absence of Primary Sclerosing Cholangitis and a Normal Microsatellite Instability Profile.

Authors:  Brett Matthew Lowenthal; Ann M Ponsford Tipps
Journal:  Case Rep Pathol       Date:  2017-01-31

6.  Clinicopathological and prognostic evaluations of anorectal cancer after fecal diversion for patients with Crohn's disease.

Authors:  Hirosuke Kuroki; Akira Sugita; Kazutaka Koganei; Kenji Tatsumi; Ryo Futatsuki; Eiichi Nakao; Nao Obara; Katsuhiko Arai
Journal:  BMC Gastroenterol       Date:  2021-04-13       Impact factor: 3.067

7.  Clinicopathological Characteristics and Surgical Outcomes of Crohn Disease-Associated Colorectal Malignancy.

Authors:  Yoo Na Lee; Jong Lyul Lee; Chang Sik Yu; Jong Beom Kim; Seok-Byung Lim; In Ja Park; Young Sik Yoon; Chan Wook Kim; Suk-Kyun Yang; Byong Duk Ye; Sang Hyoung Park; Jin Cheon Kim
Journal:  Ann Coloproctol       Date:  2021-04-30

8.  Risk factors for colorectal neoplasia in patients with underlying inflammatory bowel disease: a multicenter study.

Authors:  Xian-Rui Wu; Xiao-Bin Zheng; Yan Huang; Qian Cao; Hong-Jie Zhang; Ying-Lei Miao; Kai-Fang Zou; Min Chen; Fa-Ming Zhang; Qiao Mei; David Gonzalo; Daniela Allende; Pin-Jin Hu; Bo Shen; Xiu-Li Liu; Ping Lan
Journal:  Gastroenterol Rep (Oxf)       Date:  2018-12-13

9.  Colorectal cancer in Crohn's colitis is associated with advanced tumor invasion and a poorer survival compared with ulcerative colitis: a retrospective dual-center study.

Authors:  Leonie E Vetter; Susanne Merkel; Alan Bénard; Christian Krautz; Maximilian Brunner; Anke Mittelstädt; Nicolas Schlegel; Armin Wiegering; Christoph-Thomas Germer; Klaus Weber; Robert Grützmann; Georg F Weber
Journal:  Int J Colorectal Dis       Date:  2020-09-12       Impact factor: 2.571

Review 10.  Inflammatory bowel disease-related colorectal cancer: Past, present and future perspectives.

Authors:  Snehali Majumder; Uday Nagesh Shivaji; Rangarajan Kasturi; Alben Sigamani; Subrata Ghosh; Marietta Iacucci
Journal:  World J Gastrointest Oncol       Date:  2022-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.